Comparison between standard and reduced volume radiotherapy in bladder preservation trimodality protocol for muscle-invasive bladder cancer patients

被引:11
|
作者
Arafat, Waleed [1 ,2 ,3 ]
Darwish, Azza [1 ]
Naoum, George E. [2 ]
Sameh, Wael [4 ]
El Husseiny, Gamal [1 ]
Abd-El-Gawad, Fathy [1 ]
Samir, Mostafa [2 ]
机构
[1] Univ Alexandria, Fac Med, Oncol Dept, Alexandria, Egypt
[2] Alexandria Comprehens Canc Ctr, Alexandria, Egypt
[3] Univ Alabama Birmingham, 1720 2nd Ave S, Birmingham, AL 35233 USA
[4] Univ Alexandria, Urol Dept, Fac Med, Alexandria, Egypt
来源
ECANCERMEDICALSCIENCE | 2016年 / 10卷
关键词
bladder cancer; lymph nodes; radiotherapy; trimodality protocol;
D O I
10.3332/ecancer.2016.682
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Aim: Our aim is to compare the toxicity, pelvic nodal relapse, and overall survival of whole bladder irradiation only to the standard technique of whole pelvis irradiation followed by bladder boost in patients with muscle-invasive bladder carcinoma undergoing bladder preservation protocol. Material and method: A total of 60 patients with transitional cell carcinoma, stage T2-3, N0, M0 bladder cancer were subjected to maximal transurethral resection bladder tumour (TURB). Then, the patients were randomised into two groups: group I (30 patients) to receive whole pelvis radiotherapy 44 Gy followed by 20 Gy bladder boost. While group II (30 patients) were randomised to receive whole bladder radiotherapy alone for a total dose of 64 Gy. In both groups, concomitant cisplatin and paclitaxel were given weekly throughout the whole course of radiotherapy where conventional 2 Gy/fraction were used. Additionally, four cycles of adjuvant cisplatin and paclitaxel were given after the end of the chemoradiotherapy induction course. Results: The first assessment after the induction chemoradiotherapy showed that complete response was achieved in 73.3% of patients in group I and 76.7% of the patients in group II. After a median follow-up of 2 years, regional relapse occurred in 7.1% of patients in group I and 10.3% in group II. (p = 1). Distant metastases were detected in 17.9% of patient in group I and 13.8% in group II (p = 0.73). The 2-year disease-free survival was 60% in group I and 63.3% in group II (p = 0.79). The whole 2-year overall survival was 75% in group I and 79.3% in group II (p = 0.689). Radiation gastrointestinal (GI) acute toxicity was higher in group I than in group II (p = 0.001), while late GI radiation toxicity was comparable in both groups. Conclusion: Treating the bladder only, without elective pelvic nodal irradiation, did not compromise pelvic control rate, but significantly decreased the acute radiation toxicity.
引用
收藏
页数:13
相关论文
共 50 条
  • [22] Radiotherapy for Muscle-invasive Bladder Cancer in Very Elderly Patients
    Maebayashi, Toshiya
    Ishibashi, Naoya
    Aizawa, Takuya
    Sakaguchi, Masakuni
    Sato, Katsuhiko
    Matsui, Tsuyoshi
    Yamaguchi, Kenya
    Takahashi, Satoru
    ANTICANCER RESEARCH, 2016, 36 (09) : 4763 - 4769
  • [23] Conditional Survival Probabilities Following Bladder Preservation for Patients With Muscle-Invasive Bladder Cancer
    Mishra, M. V.
    Dan, T.
    Louie, A. V.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2015, 93 (03): : S24 - S24
  • [24] Long-term outcomes of bladder preservation in muscle-invasive bladder cancer patients
    Satiti, A. D.
    Mistry, H.
    Song, Y. P.
    Choudhury, A.
    ANNALS OF ONCOLOGY, 2019, 30
  • [25] The role of biomarkers in bladder preservation management of muscle-invasive bladder cancer
    Mitin, Timur
    Choudhury, Ananya
    WORLD JOURNAL OF UROLOGY, 2019, 37 (09) : 1767 - 1772
  • [26] Bladder preservation in muscle-invasive bladder cancer by conservative surgery and radiochemotherapy
    Dunst, J
    Rödel, C
    Zietman, A
    Schrott, KM
    Sauer, R
    Shipley, WU
    SEMINARS IN SURGICAL ONCOLOGY, 2001, 20 (01): : 24 - 32
  • [27] Patterns of Bladder Preservation Therapy Utilization for Muscle-Invasive Bladder Cancer
    Rose, Tracy L.
    Deal, Allison M.
    Ladoire, Sylvain
    Crehange, Gilles
    Galsky, Matthew D.
    Rosenberg, Jonathan E.
    Bellmunt, Joaquim
    Wimalasingham, Akhila
    Wong, Yu-Ning
    Harshman, Lauren C.
    Chowdhury, Simon
    Niegisch, Guenter
    Liontos, Michalis
    Yu, Evan Y.
    Pal, Sumanta K.
    Chen, Ronald C.
    Wang, Andrew Z.
    Nielsen, Matthew E.
    Smith, Angela B.
    Milowsky, Matthew, I
    BLADDER CANCER, 2016, 2 (04) : 405 - 413
  • [28] Molecular biomarkers in bladder preservation therapy for muscle-invasive bladder cancer
    Miyamoto, David T.
    Mouw, Kent W.
    Feng, Felix Y.
    Shipley, William U.
    Efstathiou, Jason A.
    LANCET ONCOLOGY, 2018, 19 (12): : E683 - E695
  • [29] The role of biomarkers in bladder preservation management of muscle-invasive bladder cancer
    Timur Mitin
    Ananya Choudhury
    World Journal of Urology, 2019, 37 : 1767 - 1772
  • [30] BLADDER PRESERVATION WITH IMAGE-GUIDED RADIOTHERAPY FOR ELDERLY PATIENTS WITH MUSCLE-INVASIVE BLADDER CANCER: A SINGLE INSTUTION EXPERIENCE
    Aynaci, Ozlem
    Serdar, Lasif
    Zengin, Ahmet Yasar
    Savli, Evrim
    Uslu, Gonca Hanedan
    Gedik, Sonay
    TURKISH JOURNAL OF GERIATRICS-TURK GERIATRI DERGISI, 2021, 24 (02): : 174 - 184